Epsilogen announces significant expansion of management team with three new senior hires
26.4.2023 09:00:00 EEST | Business Wire | Press release
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E (IgE) antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team. Nick Robbins-Cherry joins as Chief Financial Officer, Andrew Calam as Vice President of Clinical Operations and Elizabeth Hardaker as Vice President of Biology.
Nick Robbins-Cherry, CFO, brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Most recently, Nick was CFO of Ixaka Ltd, a private cell and gene therapy company. Prior to this, Nick was CFO at Midatech Pharma PLC, a listed pharmaceutical business with operations in the UK and Spain. He successfully steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises. Nick is a Chartered Accountant and holds an MBA.
Andrew Calam, VP of Clinical Operations, has over 25 years of experience in the life sciences industry, holding both management and executive positions in the contract research organisation (CRO) and biotechnology sectors, leading and supporting pharmaceutical development. Andrew started his career within the bioanalytical space, before turning his focus to project management. He has a track record of leading multinational teams with responsibility for all aspects of clinical trial management from phase I to phase III trials. Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and management of several clinical programs for targeted cancer therapies.
Elizabeth Hardaker, VP of Biology, joins Epsilogen with over 15 years’ experience in the pharmaceutical industry. Most recently, Elizabeth was a Senior Director at AstraZeneca, leading a team supporting preclinical research in Oncology. Previously, Elizabeth worked at Evotec in the inflammation and immunology group, and Novartis in the respiratory group. Throughout her career Elizabeth has been the biology lead on a number of projects across the drug discovery process, ranging from target validation to clinical trials. Elizabeth has a PhD from the National Heart and Lung Institute, Imperial College and a Masters in Biochemistry from Bath University.
Tim Wilson, Chief Executive Officer of Epsilogen, commented:
“We are delighted to have Elizabeth, Andrew and Nick join our leadership team and we are pleased that we have been able to attract such high-calibre people to Epsilogen. They join the Company at an exciting stage of its development with lead asset MOv18 IgE having successfully completed a phase I clinical trial in ovarian cancer patients and progress being made within our IgE-based therapeutic platforms.”
ENDS
About Epsilogen Ltd
Epsilogen is a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer. IgE’s natural function is to provide immunological defense against certain parasites. This functionality makes it an ideal treatment of solid tumours due to its strong potency, enhanced tumour access and long tissue half-life.
Epsilogen’s lead product candidate, MOv18 IgE, is the first therapeutic IgE antibody to enter the clinic and encouraging data from a phase I trial demonstrated MOv18 IgE to be safe and well tolerated with early signs of clinical activity also seen. The company is also developing a proprietary IGEGTM antibody platform combining elements from both IgE and IgG antibodies into novel and proprietary antibody molecules with enhanced functionality.
Epsilogen began operations in 2017 as a spin out of King’s College London and has attracted investment funding from top tier investors including Epidarex Capital, Novartis Venture Fund, British Patient Capital, 3B Future Health Fund, ALSA Ventures and Schroders Capital. Find out more at epsilogen.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230425005971/en/
Contact information
Communications advisor to Epsilogen Ltd:
Simon Conway / Rob Winder
FTI Consulting
epsilogen@fticonsulting.com
+44 (0)20 3727 1000
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TOURISE and Oxford Economics Release New Global Report on Tourism Resilience in an Era of Permanent Disruption17.8.2026 17:33:00 EEST | Press release
TOURISE, in collaboration with Oxford Economics, today released a new report, “Resilience in a World that Doesn’t Reset: Redesigning Tourism for an Era of Permanent Disruption.” The analysis of 85 major crises over two decades shows a clear pattern: in a world defined by continuous shocks, destinations that act before disruption hits recover up to 1.5 times faster than those that wait. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260817880835/en/ “In a world that does not reset between crises, disruption is a constant feature of the global tourism landscape,” said His Excellency Ahmed Al-Khateeb, Minister of Tourism of Saudi Arabia and Chairman of TOURISE. “The real test for destinations measures how they prepare for volatility, protect traveler confidence, and maintain continuity ahead of such events.” Using the current Middle East crisis as a lens, where Gulf hubs carry roughly 14 percent of global transit traffic, the r
The Expensify Visa® Commercial Card Brings New Proactive Spend Controls to 14 Countries17.8.2026 16:00:00 EEST | Press release
Expensify, Inc. (Nasdaq: EXFY), the easiest way to manage expenses, travel, and corporate cards, today expanded the reach of Expensify Card spend rules, the market-leading way for businesses to control corporate card spend before it happens. Available to businesses in 14 countries, spend rules let admins decide exactly how, where, and when each Expensify Card can be used, so only compliant transactions go through. Unlike traditional corporate cards that rely on after-the-fact expense review, the Expensify Card enforces policy at the point of purchase. Admins set the rules once, and the card handles the rest. With Expensify Card spend rules, admins can: Lock a card to a subscription. Give each recurring SaaS tool its own virtual card, so a vendor can only ever charge what it should. If the card owner changes teams or leaves, the subscription keeps running, with no swapping cards and no missed payments. Cover a one-time purchase. Issue a virtual card for a single transaction like event r
Riskified Analysis Finds Travel Fraudsters Are Adapting Faster Than Traditional Signals Can Keep Up, With May Flight Risk Up 32%17.8.2026 15:30:00 EEST | Press release
Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today released new findings from its Travel Industry Insights report, revealing how sophisticated fraud rings and AI-enabled fraudsters are evolving their tactics across airlines, hotels, and online travel platforms. Riskified’s analysis shows that fraudsters are increasingly adapting their behavior to resemble legitimate travelers, making traditional fraud indicators less reliable and creating new challenges for travel merchants. Riskified’s analysis of hundreds of millions of travel transactions across flights, hotels, and land transportation found that flight fraud risk increased through the first five months of 2026, with May 2026 marking the sharpest year-over-year increase at 32% compared to May 2025. The findings show that sophisticated fraud activity is not limited to predictable travel peaks, with organized fraud rings continuously adjusting their methods throughout the year. Riskified's travel n
PIF Delivers Strong Revenue and Profit Growth in 202517.8.2026 14:54:00 EEST | Press release
PIF today published its 2025 Annual Report demonstrating strong financial performance and continued progress against its long-term objectives. As a long-term investor with a unique mandate to drive the economic transformation of Saudi Arabia and deliver sustainable financial returns, PIF maintained a diversified portfolio in 2025, balancing returns with national impact and long-term resilience. Maintaining Financial Discipline In 2025, revenue rose 9% year on year to $120 billion, while net profit more than doubled to $17 billion, supported by stronger contributions from maturing portfolio companies. PIF retained over $900 billion in assets under management and achieved an annualized total shareholder return of 5.8% since 2017. Total shareholder return in 2025 was positively driven by increased dividends from portfolio companies and returns from financial investments. It was also impacted by downward movements in the valuations of some assets, as a result of wider market conditions, an
Foundever Successfully Closes a Holistic Recapitalization, Reducing its Debt by Nearly $900 Million and Strengthening its Financial Position for Long-Term Growth17.8.2026 14:30:00 EEST | Press release
Foundever Group S.A.® (“Foundever” or the “Company”) – a global leader in integrated customer experience, digital operations and analytics services, today announced that it has successfully closed a holistic recapitalization (the “Transaction”) in coordination with 95.4% of the lenders under its term loan facility (“Term Loan Lenders”), 100% of its revolving credit facility lenders (“RCF Lenders”), and the Company’s existing majority shareholders. The Transaction meaningfully strengthens Foundever’s financial foundation and positions the Company to invest in its growth strategy. Key terms of the Transaction include: Company's existing majority shareholders invest $225 million into common equity. Term loan facility exchange reduces the Company's total debt by nearly $900 million. Revolving credit facility maturity date is extended by more than four years to December 2030, and term loan maturity date is extended by more than 2.5 years to March 2031. Certain of the Company's RCF Lenders p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom